Nektar Therapeutics
NKTR Real Time Price USDRecent trades of NKTR by members of U.S. Congress
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by NKTR's directors and management
Government lobbying spending instances
-
$50,000 Jan 20, 2022 Issue: Health Issues
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Health Issues
-
$50,000 Apr 20, 2021 Issue: Health Issues
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$60,000 Jul 20, 2020 Issue: Health Issues
-
$14,000 Jul 20, 2020 Issue: Pharmacy
-
$60,000 Apr 26, 2020 Issue: Health Issues
-
$60,000 Feb 25, 2020 Issue: Health Issues
-
$50,000 Jan 21, 2020 Issue: Health Issues
-
$14,000 Jan 15, 2020 Issue: Pharmacy
-
$20,000 Jan 10, 2020 Issue: Pharmacy
-
$20,000 Oct 16, 2019 Issue: Pharmacy
-
$50,000 Oct 08, 2019 Issue: Health Issues
-
$50,000 Jul 18, 2019 Issue: Health Issues
-
$20,000 Jul 15, 2019 Issue: Pharmacy
-
$50,000 Apr 12, 2019 Issue: Health Issues
-
$20,000 Apr 11, 2019 Issue: Pharmacy
-
$50,000 Jan 20, 2019 Issue: Health Issues
-
$20,000 Jan 18, 2019 Issue: Pharmacy
-
$20,000 Oct 18, 2018 Issue: Pharmacy
-
$50,000 Oct 16, 2018 Issue: Health Issues
-
$108,000 Oct 16, 2018 Issue: Pharmacy
-
$20,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
-
$50,000 Jul 20, 2018 Issue: Health Issues
-
$21,600 Jul 18, 2018 Issue: Pharmacy
-
$20,000 Apr 20, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
-
$60,000 Apr 18, 2018 Issue: Health Issues
-
$72,000 Apr 17, 2018 Issue: Pharmacy
-
$20,000 Jan 22, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
-
$144,000 Jan 19, 2018 Issue: Pharmacy
-
$30,000 Jan 18, 2018 Issue: Health Issues
-
$20,000 Oct 20, 2017 Issue: Taxation/Internal Revenue Code Pharmacy
-
$20,000 Oct 20, 2017 Issue: Pharmacy
-
$30,000 Oct 13, 2017 Issue: Health Issues
-
$20,000 Apr 20, 2017 Issue: Pharmacy
-
$60,000 Apr 01, 2017 Issue: Pharmacy
-
$20,000 Jan 23, 2017 Issue: Pharmacy
-
$60,000 Jan 19, 2017 Issue: Pharmacy
-
$20,000 Oct 20, 2016 Issue: Pharmacy
-
$60,000 Oct 20, 2016 Issue: Pharmacy
-
$20,000 Jul 20, 2016 Issue: Pharmacy
-
$60,000 Jul 20, 2016 Issue: Pharmacy
-
$20,000 Apr 20, 2016 Issue: Pharmacy
-
$60,000 Apr 20, 2016 Issue: Pharmacy
-
$10,000 Jan 20, 2016 Issue: Pharmacy
-
$90,000 Jan 20, 2016 Issue: Pharmacy
-
$90,000 Oct 20, 2015 Issue: Pharmacy
-
$90,000 Jul 20, 2015 Issue: Pharmacy
-
$90,000 Apr 20, 2015 Issue: Pharmacy
-
$100,000 Jan 20, 2015 Issue: Pharmacy
-
$90,000 Oct 20, 2014 Issue: Pharmacy
-
$90,000 Jul 21, 2014 Issue: Pharmacy
-
$10,000 Oct 01, 2008 Issue: Health Issues
-
$10,000 Jul 18, 2008 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Immunotherapeutic tumor treatment method Aug. 06, 2024
-
Patent Title: Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods Jul. 16, 2024
-
Patent Title: Immunotherapeutic tumor treatment method Jul. 09, 2024
-
Patent Title: Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition Jun. 25, 2024
-
Patent Title: Method of making releasable polymeric reagents Mar. 19, 2024
-
Patent Title: Alkoxylation methods Dec. 05, 2023
-
Patent Title: Multi-arm polymeric prodrug conjugates of taxane-based compounds Nov. 14, 2023
-
Patent Title: Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods Sep. 05, 2023
-
Patent Title: Multi-arm polymeric alkanoate conjugates Jun. 13, 2023
-
Patent Title: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Apr. 25, 2023
-
Patent Title: Conjugates of a factor viii moiety having an oxime-containing linkage Apr. 18, 2023
-
Patent Title: Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds Mar. 28, 2023
-
Patent Title: Oligomer-corticosteroid conjugates Oct. 11, 2022
-
Patent Title: Polymer derivatives having particular atom arrangements Sep. 20, 2022
-
Patent Title: Polymer-sunitinib conjugates Aug. 23, 2022
-
Patent Title: Polymer-des-ethyl sunitinib conjugates Aug. 09, 2022
-
Patent Title: Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy May. 03, 2022
-
Patent Title: Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates Mar. 08, 2022
-
Patent Title: N-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor Feb. 08, 2022
-
Patent Title: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Jan. 11, 2022
-
Patent Title: Method of making a water-soluble polymer-factor viii moiety conjugate Oct. 12, 2021
-
Patent Title: Chemically modified small molecules Sep. 28, 2021
-
Patent Title: Method of preparing carboxylic acid functionalized polymers Sep. 07, 2021
-
Patent Title: Kappa opioid agonists and uses thereof Sep. 07, 2021
-
Patent Title: Method of refolding an interleukin-2 (il-2) protein Aug. 17, 2021
-
Patent Title: Methods of treating cyp2d6 alternative metabolizers Jun. 15, 2021
-
Patent Title: Polymer-semaxanib moiety conjugates May. 18, 2021
-
Patent Title: Conjugates of an il-2 moiety and a polymer Mar. 30, 2021
-
Patent Title: Particulate materials Mar. 16, 2021
-
Patent Title: Methods for preparing functionalized polymers from polymer alcohols Mar. 09, 2021
-
Patent Title: Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds Jan. 19, 2021
-
Patent Title: Oligomer-beta blocker conjugates Jan. 05, 2021
-
Patent Title: Oligomer-phenothiazine conjugates Dec. 22, 2020
-
Patent Title: Opioid agonists and uses thereof Dec. 15, 2020
-
Patent Title: Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine Nov. 24, 2020
-
Patent Title: Protease inhibitors having enhanced features Oct. 20, 2020
-
Patent Title: Compositions of particulate coformulation Oct. 13, 2020
-
Patent Title: Il-2rβ-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody Sep. 29, 2020
-
Patent Title: N-maleimidyl polymer derivatives Sep. 15, 2020
-
Patent Title: Morphinan derivatives for the treatment of neuropathic pain Sep. 08, 2020
-
Patent Title: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Sep. 01, 2020
-
Patent Title: Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds Aug. 11, 2020
-
Patent Title: Composition comprising a polymeric reagent Jun. 30, 2020
-
Patent Title: Polymer-sunitinib conjugates Jun. 16, 2020
-
Patent Title: Combination-based treatment method May. 19, 2020
-
Patent Title: Polymer derivatives having particular atom arrangements May. 12, 2020
-
Patent Title: Compositions and methods for achieving sustained therapeutic drug concentrations in a subject Jan. 07, 2020
-
Patent Title: Oligomer-phenothiazine conjugates Nov. 26, 2019
-
Patent Title: Polymer-semaxanib moiety conjugates Nov. 05, 2019
-
Patent Title: Multi-arm polymer prodrugs Nov. 05, 2019
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of NKTR in WallStreetBets Daily Discussion
Recent insights relating to NKTR
Recent picks made for NKTR stock on CNBC
ETFs with the largest estimated holdings in NKTR
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NKTR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.